Tonix Pharmaceuticals Holding Corp. has provided an update on their investigational new biologic, TNX-1500, which is designed to address organ transplant rejection and autoimmune disorders. TNX-1500 is a third-generation anti-CD40L monoclonal antibody, re-engineered to enhance Fc receptor modulation while maintaining FcRn function. The company has completed Phase 1 studies and is preparing to initiate Phase 2 studies in kidney transplant recipients. Potential future indications include Sjögren's Syndrome and Systemic Lupus Erythematosus, among others. Collaborations are ongoing with institutions for heart, kidney, and bone marrow transplantation research in non-human primates. TNX-1500 has not yet been approved for any indication. You can access the full presentation through the link below.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。